# Novo Nordisk Fonden > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/novonordiskfonden). ## Overview Novo Nordisk Fonden is a Danish philanthropic foundation that owns the Novo Nordisk Group and holds a controlling interest in Novonesis. Through its ownership and grant-making activities, it combines long-term stewardship of industrial assets with support for research, innovation, and education. ## Products & services • Philanthropic grants for research and education • Strategic project funding • Ownership and stewardship of operating companies • Grant assessment and committee oversight - **Grant-making** (60%) — Funding for research, innovation, education, and standalone projects. - **Ownership stewardship** (25%) — Long-term control and governance of the Novo Nordisk Group and other holdings. - **Investment income** (15%) — Returns and distributions from owned companies and financial assets. - Philanthropic grants for research and education - Strategic project funding - Ownership and stewardship of operating companies - Grant assessment and committee oversight ## Customers The Foundation's direct beneficiaries are researchers, universities, and educational institutions that receive grants and project support. Indirectly, its governance and capital allocation activities affect the Novo Nordisk Group, Novonesis, and other affiliated holdings. Its grant process also serves expert committees and advisory bodies that review applications and shape funding decisions. - **Research institutions** (primary) — Universities and research centers that receive funding for scientific programs and projects. - **Education beneficiaries** (secondary) — Schools, training programs, and education initiatives supported through grants. - **Owned operating companies** (primary) — Novo Nordisk Group and other holdings that depend on long-term ownership and governance. - **Innovation projects** (secondary) — Standalone and strategic initiatives funded to advance science, health, and innovation. - Researchers seeking support for scientific projects - Universities and academic institutions - Education and innovation initiatives - Novo Nordisk Group as an owned operating platform - Novonesis and other affiliated holdings ## Geography Novo Nordisk Fonden is headquartered in Denmark and its activities are anchored there through governance, ownership, and grant administration. The Foundation supports projects internationally, but the report excerpt does not provide a formal geographic revenue split. Its exposure is therefore tied less to sales geography than to the countries where funded research, owned subsidiaries, and related stakeholders operate. - Headquartered in Denmark - Governance and administration are centered in Denmark - Grants can support international research and education - Ownership exposure follows the operating footprint of holdings - No country revenue split disclosed in the excerpt ## Strategy The Foundation's strategy is to allocate capital through grants while preserving long-term control of key industrial holdings. It uses committees, advisory panels, and peer review to direct funding toward research, innovation, and education with a high level of selection discipline. - **Disciplined grant allocation** (short-term) — The Foundation wants funding decisions to remain fair, expert-led, and mission aligned. - **Long-term ownership stewardship** (long-term) — Controlling holdings require stable governance and capital allocation over many years. - **Targeted support for science and education** (medium-term) — Grant funding is the main way the Foundation advances its charitable mission. - Preserve long-term ownership of key holdings - Direct capital to research, innovation, and education - Use peer review and committees to screen grants - Support strategic and standalone projects - Maintain governance over affiliated companies ## Risks The main risks are concentration in a small number of major holdings and dependence on the quality of governance and grant selection. As a foundation, it also faces legal, regulatory, and reputational risk around ownership rights, related-party transactions, and the fairness of grant allocation. - **Concentration in major holdings** [high] — A large share of value and governance influence is tied to a small number of affiliated companies. - **Grant-awarding disputes** [medium] — Funding decisions rely on committee judgment and eligibility rules, which can be challenged. - **Regulatory and legal challenge** [medium] — The report notes legal challenges related to the 340B program and changing legal landscape for related matters. - Concentration in Novo Nordisk and other key holdings - Grant decisions may be challenged on fairness or eligibility - Legal and regulatory risk around ownership structures - Related-party transactions require careful governance - Reputational risk if funding or governance is disputed ## Accounting The Foundation reports under IFRS and recognizes grants when it becomes obligated to the recipient, which can create timing differences between commitment and expense recognition. Its consolidated accounts also depend on investment accounting, dividend recognition from subsidiaries, and fair-value judgments for financial assets and liabilities. - **Grant recognition timing** — Can shift reported operating results across periods - **Consolidation of subsidiaries** — Determines which entities are included in group accounts - **Dividend and investment income** — Affects reported income and distributable capacity - **Fair value measurements** — Can create volatility in reported equity and profit - Grant expense is recognized when the obligation arises - Investment income depends on subsidiary dividends - Ownership interests require consolidation judgments - Fair-value estimates affect financial assets and liabilities - Related-party transactions need clear disclosure --- *Last updated: 2026-10-24T15:14:39.395409+00:00*